Cancer Research Annual Meeting 2010 EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 59, 4204-4207, September 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goan, Y.-G.
Right arrow Articles by Yen, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goan, Y.-G.
Right arrow Articles by Yen, Y.
[Cancer Research 59, 4204-4207, September 1, 1999]
© 1999 American Association for Cancer Research

Advances in Brief

Overexpression of Ribonucleotide Reductase as a Mechanism of Resistance to 2,2-Difluorodeoxycytidine in the Human KB Cancer Cell Line1

Yih-Gang Goan, Bingsen Zhou, Edward Hu, Shu Mi and Yun Yen2

Division of Thoracic Surgery, Department of Surgery, Veterans General Hospital-Kaohsiung, and National Yang-Ming University, Taiwan, Republic of China [Y-G. G.]; and Department of Medical Oncology, City of Hope National Medical Center, Duarte, California 91010 [B. Z., E. H., S. M., Y. Y.]

In this study, human oropharyngeal epidermoid carcinoma KB cells that were resistant to 2,2-difluorodeoxycytidine (dFdCyd) were selected and designated the KB-Gem clone. The KB parental cell line IC50 was 0.3 µM dFdCyd, as compared with the KB-Gem clone IC50 of 32 µM dFdCyd. The KB-Gem clone demonstrated overexpression of ribonucleotide reductase (RR) M2 subunit mRNA (9-fold) and overexpression of M2 protein (2-fold); RR activity was 2.3-fold higher than the KB parental cell line. Both the dATP and dCTP pools of the KB-Gem clone increased 2-fold over the parental cell line, with no change in the dGTP and dTTP pools. Reverse transcriptase-PCR was used to clone the cDNA of deoxycytidine kinase (DCK). Resulting sequences revealed two silent mutations in the KB-Gem clone. The amino acid sequence of the DCK protein and mRNA expression remained unchanged. The KB-Gem clone’s DCK enzyme activity was 56% of that of the parental cell line. After the endogenous dNTPs were removed with a G-25 column, no difference was evident between the enzyme activities of the KB-Gem clone and parental cells. Thus, contrary to previous hypotheses, DCK deficiency does not play the primary role in the resistance mechanism of dFdCyd, accepting a secondary role to the overexpression of the target gene, RR, and pool expansion.




This article has been cited by other articles:


Home page
 The OncologistHome page
S. Y. Rha, H. C. Jeung, Y. H. Choi, W. I. Yang, J. H. Yoo, B. S. Kim, J. K. Roh, and H. C. Chung
An Association Between RRM1 Haplotype and Gemcitabine-Induced Neutropenia in Breast Cancer Patients
Oncologist, June 1, 2007; 12(6): 622 - 630.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P Ceppi, M Volante, S Novello, I Rapa, K. Danenberg, P. Danenberg, A Cambieri, G Selvaggi, S Saviozzi, R Calogero, et al.
ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine
Ann. Onc., December 1, 2006; 17(12): 1818 - 1825.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
T. Oguri, H. Achiwa, S. Sato, Y. Bessho, Y. Takano, M. Miyazaki, H. Muramatsu, H. Maeda, T. Niimi, and R. Ueda
The determinants of sensitivity and acquired resistance to gemcitabine differ in non-small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity.
Mol. Cancer Ther., July 1, 2006; 5(7): 1800 - 1806.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
E. Giovannetti, V. Mey, S. Nannizzi, G. Pasqualetti, M. Del Tacca, and R. Danesi
Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer.
Mol. Cancer Ther., June 1, 2006; 5(6): 1387 - 1395.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Giovannetti, M. Del Tacca, V. Mey, N. Funel, S. Nannizzi, S. Ricci, C. Orlandini, U. Boggi, D. Campani, M. Del Chiaro, et al.
Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.
Cancer Res., April 1, 2006; 66(7): 3928 - 3935.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. Aghi, S. Rabkin, and R. L. Martuza
Effect of Chemotherapy-Induced DNA Repair on Oncolytic Herpes Simplex Viral Replication
J Natl Cancer Inst, January 4, 2006; 98(1): 38 - 50.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. A. van de Wiel, J. L. Costa, K. Smid, C. B.M. Oudejans, A. M. Bergman, G. A. Meijer, G. J. Peters, and B. Ylstra
Expression Microarray Analysis and Oligo Array Comparative Genomic Hybridization of Acquired Gemcitabine Resistance in Mouse Colon Reveals Selection for Chromosomal Aberrations
Cancer Res., November 15, 2005; 65(22): 10208 - 10213.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. M. Bergman, P. P. Eijk, V. W.T. Ruiz van Haperen, K. Smid, G. Veerman, I. Hubeek, P. van den IJssel, B. Ylstra, and G. J. Peters
In vivo Induction of Resistance to Gemcitabine Results in Increased Expression of Ribonucleotide Reductase Subunit M1 as the Major Determinant
Cancer Res., October 15, 2005; 65(20): 9510 - 9516.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
L. P. Jordheim, O. Guittet, M. Lepoivre, C. M. Galmarini, and C. Dumontet
Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells
Mol. Cancer Ther., August 1, 2005; 4(8): 1268 - 1276.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. A. Desai, R. L. Schilsky, A. Young, L. Janisch, W. M. Stadler, N. J. Vogelzang, S. Cadden, J. A. Wright, and M. J. Ratain
A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors
Ann. Onc., June 1, 2005; 16(6): 958 - 965.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Ogawa, H. Hori, T. Ohta, K. Onozato, M. Miyahara, and Y. Komada
Sensitivity to Gemcitabine and Its Metabolizing Enzymes in Neuroblastoma
Clin. Cancer Res., May 1, 2005; 11(9): 3485 - 3493.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Akada, T. Crnogorac-Jurcevic, S. Lattimore, P. Mahon, R. Lopes, M. Sunamura, S. Matsuno, and N. R. Lemoine
Intrinsic Chemoresistance to Gemcitabine Is Associated with Decreased Expression of BNIP3 in Pancreatic Cancer
Clin. Cancer Res., April 15, 2005; 11(8): 3094 - 3101.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Grant and P. Dent
Kinase Inhibitors and Cytotoxic Drug Resistance
Clin. Cancer Res., April 1, 2004; 10(7): 2205 - 2207.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. S. Duxbury, H. Ito, M. J. Zinner, S. W. Ashley, and E. E. Whang
Inhibition of Src Tyrosine Kinase Impairs Inherent and Acquired Gemcitabine Resistance in Human Pancreatic Adenocarcinoma Cells
Clin. Cancer Res., April 1, 2004; 10(7): 2307 - 2318.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Rosell, K. D. Danenberg, V. Alberola, G. Bepler, J. J. Sanchez, C. Camps, M. Provencio, D. Isla, M. Taron, P. Diz, et al.
Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients
Clin. Cancer Res., February 15, 2004; 10(4): 1318 - 1325.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Shao, B. Zhou, L. Zhu, W. Qiu, Y.-C. Yuan, B. Xi, and Y. Yen
In Vitro Characterization of Enzymatic Properties and Inhibition of the p53R2 Subunit of Human Ribonucleotide Reductase
Cancer Res., January 1, 2004; 64(1): 1 - 6.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Yen
Ribonucleotide Reductase Subunit One as Gene Therapy Target: Commentary re: M-Y. Cao et al., Adenovirus-mediated Ribonucleotide Reductase R1 Gene Therapy of Human Colon Adenocarcinoma. Clin. Cancer Res., 9: 4304-4308, 2003.
Clin. Cancer Res., October 1, 2003; 9(12): 4304 - 4308.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Murren, M. Modiano, C. Clairmont, P. Lambert, N. Savaraj, T. Doyle, and M. Sznol
Phase I and Pharmacokinetic Study of Triapine, a Potent Ribonucleotide Reductase Inhibitor, Administered Daily for Five Days in Patients with Advanced Solid Tumors
Clin. Cancer Res., September 15, 2003; 9(11): 4092 - 4100.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Lee, A. Vassilakos, N. Feng, V. Lam, H. Xie, M. Wang, H. Jin, K. Xiong, C. Liu, J. Wright, et al.
GTI-2040, an Antisense Agent Targeting the Small Subunit Component (R2) of Human Ribonucleotide Reductase, Shows Potent Antitumor Activity against a Variety of Tumors
Cancer Res., June 1, 2003; 63(11): 2802 - 2811.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Xue, B. Zhou, X. Liu, W. Qiu, Z. Jin, and Y. Yen
Wild-Type p53 Regulates Human Ribonucleotide Reductase by Protein-Protein Interaction with p53R2 as well as hRRM2 Subunits
Cancer Res., March 1, 2003; 63(5): 980 - 986.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. K. Nowak, B. W. S. Robinson, and R. A. Lake
Gemcitabine Exerts a Selective Effect on the Humoral Immune Response: Implications for Combination Chemo-immunotherapy
Cancer Res., April 1, 2002; 62(8): 2353 - 2358.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. B. Matranga and G. I. Shapiro
Selective Sensitization of Transformed Cells to Flavopiridol-induced Apoptosis following Recruitment to S-Phase
Cancer Res., March 1, 2002; 62(6): 1707 - 1717.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. P. Jung, M. V. Motwani, and G. K. Schwartz
Flavopiridol Increases Sensitization to Gemcitabine in Human Gastrointestinal Cancer Cell Lines and Correlates with Down-Regulation of Ribonucleotide Reductase M2 Subunit
Clin. Cancer Res., August 1, 2001; 7(8): 2527 - 2536.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1999 by the American Association for Cancer Research.